Display options
Cite
Braun LH, Reinert CP, Zips D, et al. Treatment outcome after radiochemotherapy in anal cancer patients staged with . Clin Transl Radiat Oncol. 2020;24:83-87doi: 10.1016/j.ctro.2020.06.008.
Braun, L. H., Reinert, C. P., Zips, D., Nikolaou, K., Pfannenberg, C., & Gani, C. (2020). Treatment outcome after radiochemotherapy in anal cancer patients staged with . Clinical and translational radiation oncology, 2483-87. https://doi.org/10.1016/j.ctro.2020.06.008
Braun, L H, et al. "Treatment outcome after radiochemotherapy in anal cancer patients staged with ." Clinical and translational radiation oncology vol. 24 (2020): 83-87. doi: https://doi.org/10.1016/j.ctro.2020.06.008
Braun LH, Reinert CP, Zips D, Nikolaou K, Pfannenberg C, Gani C. Treatment outcome after radiochemotherapy in anal cancer patients staged with . Clin Transl Radiat Oncol. 2020 Jun 18;24:83-87. doi: 10.1016/j.ctro.2020.06.008. eCollection 2020 Sep. PMID: 32642564; PMCID: PMC7334798.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Radiat Oncol. 2020 Jun 18;24:83-87. doi: 10.1016/j.ctro.2020.06.008. eCollection 2020 Sep.

Treatment outcome after radiochemotherapy in anal cancer patients staged with .

Clinical and translational radiation oncology

L H Braun, C P Reinert, D Zips, K Nikolaou, C Pfannenberg, C Gani

Affiliations

  1. Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Germany.
  2. Klinik für Strahlentherapie und Palliativmedizin, Marienhospital Stuttgart, Germany.
  3. Department of Diagnostic and Interventional Radiology, Eberhard Karls University Tubingen, Germany.
  4. German Cancer Research Center (DKFZ) Heidelberg and German Consortium for Translational Cancer Research (DKTK), Partner Site Tübingen, Tübingen, Germany.

PMID: 32642564 PMCID: PMC7334798 DOI: 10.1016/j.ctro.2020.06.008

Abstract

BACKGROUND: Anal cancer (AC) is a malignancy with increasing incidence and commonly treated with radiochemotherapy. Positron-emission tomography-computed tomography (PET/CT) has been shown to improve treatment outcome in various oncological diseases, however, for AC long-term outcome data is sparse. The aim of the present study is therefore to report outcomes in our cohort of PET/CT staged AC patients treated with radiochemotherapy.

METHODS: Patients with AC who were treated with radiochemotherapy in curative intent were included in this retrospective study if a PET/CT scan was performed pre-therapeutically. Information from PET/CT was considered for nodal and primary target volume definition. Radiotherapy dose to the primary tumor was 50-66 Gy and concomitant chemotherapy included 5-fluorouracil and mitomycin-C. The uptake of

RESULTS: A total of 60 patients were included in this study. Estimates for three-year overall survival (OS) and disease free survival (DFS) were 94.5% and 80%. Five patients developed local (n = 2) or locoregional and local (n = 3) failure. Baseline PET/CT related parameters correlated with primary tumor stage, nodal stage and tumor grading. DFS was independent of T-stage, N-stage and baseline

CONCLUSION: In this cohort of PET/CT staged AC patients, excellent outcomes for DFS were seen. PET-based markers of tumor burden correlate with local stage of AC, however, are not of prognostic relevance for disease-free survival.

© 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.

Keywords: Anal cancer; PET; Radiochemotherapy; Radiotherapy

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

  1. Radiother Oncol. 2008 Jun;87(3):376-82 - PubMed
  2. Control Clin Trials. 1996 Aug;17(4):343-6 - PubMed
  3. Ann Oncol. 2020 Feb;31(2):236-245 - PubMed
  4. Cancer. 2004 Jul 15;101(2):281-8 - PubMed
  5. Radiol Med. 2016 Jan;121(1):54-9 - PubMed
  6. PET Clin. 2020 Jan;15(1):77-87 - PubMed
  7. Dis Colon Rectum. 2009 Apr;52(4):624-31 - PubMed
  8. Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 - PubMed
  9. Pract Radiat Oncol. 2016 Sep-Oct;6(5):e149-e154 - PubMed
  10. Biomed Res Int. 2015;2015:485071 - PubMed
  11. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):63-70 - PubMed
  12. BMC Cancer. 2019 Jul 29;19(1):742 - PubMed
  13. Lancet. 2020 Apr 11;395(10231):1208-1216 - PubMed
  14. Radiother Oncol. 2010 Jun;95(3):288-91 - PubMed
  15. Eur J Radiol. 2016 Aug;85(8):1390-4 - PubMed
  16. Lancet Oncol. 2013 May;14(6):516-24 - PubMed
  17. Br J Radiol. 2017 Dec;90(1080):20170370 - PubMed
  18. N Engl J Med. 2016 Apr 14;374(15):1444-54 - PubMed
  19. Ann Surg Oncol. 2015 Oct;22(11):3574-81 - PubMed
  20. J Nucl Med. 2013 Jan;54(1):27-32 - PubMed
  21. Br J Cancer. 2009 Mar 10;100(5):693-700 - PubMed
  22. N Engl J Med. 2003 Jun 19;348(25):2500-7 - PubMed
  23. Nat Rev Clin Oncol. 2016 Jul;13(7):447-59 - PubMed
  24. Radiat Oncol. 2019 Aug 6;14(1):140 - PubMed
  25. JAMA. 2008 Apr 23;299(16):1914-21 - PubMed
  26. J Clin Oncol. 1997 May;15(5):2040-9 - PubMed
  27. Strahlenther Onkol. 2019 May;195(5):369-373 - PubMed
  28. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):54-64 - PubMed
  29. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):863-70 - PubMed
  30. Eur Radiol. 2020 Apr;30(4):1896-1907 - PubMed
  31. Acta Oncol. 2017 Dec;56(12):1734-1740 - PubMed
  32. Clin Positron Imaging. 1999 May;2(3):159-171 - PubMed
  33. Radiother Oncol. 2020 Mar;144:7-12 - PubMed
  34. J Nucl Med. 2013 Aug;54(8):1188-94 - PubMed
  35. Gastroenterol Clin Biol. 2009 May;33(5):456-8 - PubMed
  36. Adv Radiat Oncol. 2017 Apr 29;2(3):281-287 - PubMed

Publication Types